These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 26390252)
1. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. Terai H; Tan L; Beauchamp EM; Hatcher JM; Liu Q; Meyerson M; Gray NS; Hammerman PS ACS Chem Biol; 2015 Dec; 10(12):2687-96. PubMed ID: 26390252 [TBL] [Abstract][Full Text] [Related]
2. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Hammerman PS; Sos ML; Ramos AH; Xu C; Dutt A; Zhou W; Brace LE; Woods BA; Lin W; Zhang J; Deng X; Lim SM; Heynck S; Peifer M; Simard JR; Lawrence MS; Onofrio RC; Salvesen HB; Seidel D; Zander T; Heuckmann JM; Soltermann A; Moch H; Koker M; Leenders F; Gabler F; Querings S; Ansén S; Brambilla E; Brambilla C; Lorimier P; Brustugun OT; Helland A; Petersen I; Clement JH; Groen H; Timens W; Sietsma H; Stoelben E; Wolf J; Beer DG; Tsao MS; Hanna M; Hatton C; Eck MJ; Janne PA; Johnson BE; Winckler W; Greulich H; Bass AJ; Cho J; Rauh D; Gray NS; Wong KK; Haura EB; Thomas RK; Meyerson M Cancer Discov; 2011 Jun; 1(1):78-89. PubMed ID: 22328973 [TBL] [Abstract][Full Text] [Related]
3. NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. Xu C; Buczkowski KA; Zhang Y; Asahina H; Beauchamp EM; Terai H; Li YY; Meyerson M; Wong KK; Hammerman PS Mol Cancer Ther; 2015 Oct; 14(10):2382-2389. PubMed ID: 26206333 [TBL] [Abstract][Full Text] [Related]
4. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Beauchamp EM; Woods BA; Dulak AM; Tan L; Xu C; Gray NS; Bass AJ; Wong KK; Meyerson M; Hammerman PS Mol Cancer Ther; 2014 Feb; 13(2):475-82. PubMed ID: 24296828 [TBL] [Abstract][Full Text] [Related]
5. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. Bai Y; Kim JY; Watters JM; Fang B; Kinose F; Song L; Koomen JM; Teer JK; Fisher K; Chen YA; Rix U; Haura EB Cancer Res; 2014 Dec; 74(24):7217-7228. PubMed ID: 25348954 [TBL] [Abstract][Full Text] [Related]
6. Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer. Nicoś M; Powrózek T; Krawczyk P; Jarosz B; Pająk B; Sawicki M; Kucharczyk K; Trojanowski T; Milanowski J Med Oncol; 2014 Oct; 31(10):176. PubMed ID: 25173530 [TBL] [Abstract][Full Text] [Related]
7. A new target for therapy in squamous cell carcinoma of the lung. Ohashi K; Pao W Cancer Discov; 2011 Jun; 1(1):23-4. PubMed ID: 22586316 [TBL] [Abstract][Full Text] [Related]
8. Molecular basis and functional significance of Angiotensin II-induced increase in Discoidin Domain Receptor 2 gene expression in cardiac fibroblasts. George M; Vijayakumar A; Dhanesh SB; James J; Shivakumar K J Mol Cell Cardiol; 2016 Jan; 90():59-69. PubMed ID: 26674152 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of discoidin domain receptor 2-mediated lung cancer cells progression by gold nanoparticle-aptamer-assisted delivery of peptides containing transmembrane-juxtamembrane 1/2 domain. Kim D; Yeom JH; Lee B; Lee K; Bae J; Rhee S Biochem Biophys Res Commun; 2015 Aug; 464(2):392-5. PubMed ID: 26067556 [TBL] [Abstract][Full Text] [Related]
10. Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients. Miao L; Wang Y; Zhu S; Shi M; Li Y; Ding J; Yang J; Ye Q; Cai H; Zhang D; Liu H; Song Y BMC Cancer; 2014 May; 14():369. PubMed ID: 24885564 [TBL] [Abstract][Full Text] [Related]
11. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Ford CE; Lau SK; Zhu CQ; Andersson T; Tsao MS; Vogel WF Br J Cancer; 2007 Mar; 96(5):808-14. PubMed ID: 17299390 [TBL] [Abstract][Full Text] [Related]
15. Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants. Iwai LK; Payne LS; Luczynski MT; Chang F; Xu H; Clinton RW; Paul A; Esposito EA; Gridley S; Leitinger B; Naegle KM; Huang PH Biochem J; 2013 Sep; 454(3):501-13. PubMed ID: 23822953 [TBL] [Abstract][Full Text] [Related]
16. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. Pitini V; Arrigo C; Di Mirto C; Mondello P; Altavilla G Lung Cancer; 2013 Oct; 82(1):171-2. PubMed ID: 23932362 [TBL] [Abstract][Full Text] [Related]
17. Discoipyrroles A-D: isolation, structure determination, and synthesis of potent migration inhibitors from Bacillus hunanensis. Hu Y; Potts MB; Colosimo D; Herrera-Herrera ML; Legako AG; Yousufuddin M; White MA; MacMillan JB J Am Chem Soc; 2013 Sep; 135(36):13387-92. PubMed ID: 23984625 [TBL] [Abstract][Full Text] [Related]
18. A host deficiency of discoidin domain receptor 2 (DDR2) inhibits both tumour angiogenesis and metastasis. Zhang S; Bu X; Zhao H; Yu J; Wang Y; Li D; Zhu C; Zhu T; Ren T; Liu X; Yao L; Su J J Pathol; 2014 Mar; 232(4):436-48. PubMed ID: 24293323 [TBL] [Abstract][Full Text] [Related]
19. Fusion expression of DDR2 extracellular domain in insect cells and its purification and function characterization. Zhang W; Ding T; Zhang J; Su J; Yu J; Li J; Li F; Wang C; Liu N; Liu X; Ma W; Yao L J Cell Biochem; 2007 Sep; 102(1):41-51. PubMed ID: 17427955 [TBL] [Abstract][Full Text] [Related]
20. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Johnson FM; Saigal B; Talpaz M; Donato NJ Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]